| |
Welcome |
 |
Immunomic Therapeutics' website is your resource for news & updates about the Company as well a wealth of technical and informational content.
For general information about ITI, its management team and our vision, we invite you to explore the About Us section. If you are interested in learning a little basic immunology and how vaccines can be used to treat allergies, visit our Immunology 101 section. We are also planning on adding a multi-media section to further your understanding of LAMP-vax Technology and our developing vaccine product line.
|
|
About us |
|
Immunomic Therapeutics, Inc. (ITI) is a development stage biotechnology company with exceptional science for application to vaccines and vaccine immunotherapies.
The promise of our LAMP-vax Technology is to increase the effectiveness of the immune response to DNA vaccines while simplifying overall vaccine design and delivery. The LAMP-vax Technology is ideally suited for application to allergy immunotherapy and the company is planning to initiate a clinical study in 2009. There is both industry and clinical validation for this breakthrough science.
|
|
Latest news |
|
December 11th, 2009
Immunomic Therapeutics Sub-Licensee Reports on Phase II Results in AML Patients Geron reported LAMP vaccine, GRNVAC1 met its Phase II clinical endpoints. In the preliminary report, Geron said 14 of 20 patients remained in remission at the end of the study. More information is available in our News Section.
November 4th, 2009
Immunomic Therapeutics Presents to Large Audience at Mid-Atlantic Bio 2009. ITI was one of 14 regional companies selected to present at this year's conference. For additional news on this event, please visit read the press release.
October 28, 2009
New Publications Highlight Effectiveness of LAMP Technology. In a recent press release ITI reports on two new publications in the literature on applications of LAMP with excellent results. One study demonstrates the utility of the LAMP construct in providing protection for rabies and a second reports on use as an alternative to live attentuated yellow fever vaccine.
|
|
